• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axim Biotechnologies Inc (OP:AXIM)

0.0086 -0.0001 (-1.15%)
Streaming Delayed Price Updated: 2:03 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,509
Open 0.0089
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0087
Today's Range 0.0082 - 0.0089
52wk Range 0.0017 - 0.0288
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
January 20, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
January 20, 2026
Via TheNewswire.com

Performance

YTD
-25.2%
-25.2%
1 Month
-25.9%
-25.9%
3 Month
+7.5%
+7.5%
6 Month
+28.4%
+28.4%
1 Year
+258.3%
+258.3%

More News

Read More
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea
October 23, 2025
Via TheNewswire.com
News headline image
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea
October 23, 2025
Via NewMediaWire
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
March 27, 2024
Via TheNewswire.com
AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests
October 07, 2025
Via TheNewswire.com
News headline image
AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests
October 07, 2025
Via NewMediaWire
News headline image
Axim Biotechnologies Files Pre-Submission With FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test
June 24, 2025
Via NewMediaWire
News headline image
AXIM Biotechnologies Receives Medical Device Manufacturing License
May 29, 2024
Via NewMediaWire
News headline image
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
March 27, 2024
Via NewMediaWire
News headline image
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
February 20, 2024
Via NewMediaWire
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
February 20, 2024
Via TheNewswire.com
AXIM Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
December 20, 2023
Via NewMediaWire
News headline image
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
September 12, 2023
From AXIM Biotechnologies, Inc.
Via Business Wire
News headline image
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
August 01, 2023
From AXIM Biotechnologies, Inc.
Via Business Wire
News headline image
Update: AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
July 12, 2023
Via NewMediaWire
News headline image
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
July 12, 2023
Via NewMediaWire
News headline image
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
May 24, 2023
Via NewMediaWire
News headline image
AXIM Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
May 23, 2023
Via NewMediaWire
News headline image
AXIM Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays
April 11, 2023
Via NewMediaWire
News headline image
AXIM Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing
March 14, 2023
Via NewMediaWire
Topics Intellectual Property
News headline image
Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion
March 14, 2023
Via NewMediaWire
Topics Cannabis
News headline image
AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance
January 17, 2023
Via NewMediaWire
Topics Intellectual Property
News headline image
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent
December 13, 2022
From AXIM BIOTECHNOLOGIES, INC
Via GlobeNewswire
News headline image
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions
December 06, 2022
From AXIM BIOTECHNOLOGIES, INC
Via GlobeNewswire

Frequently Asked Questions

Is Axim Biotechnologies Inc publicly traded?
Yes, Axim Biotechnologies Inc is publicly traded.
What exchange does Axim Biotechnologies Inc trade on?
Axim Biotechnologies Inc trades on the OTC Traded
What is the ticker symbol for Axim Biotechnologies Inc?
The ticker symbol for Axim Biotechnologies Inc is AXIM on the OTC Traded
What is the current price of Axim Biotechnologies Inc?
The current price of Axim Biotechnologies Inc is 0.0086
When was Axim Biotechnologies Inc last traded?
The last trade of Axim Biotechnologies Inc was at 01/21/26 02:03 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap